CA2318960A1 - Utilisations pharmaceutiques de (+)-bupropion optiquement pur - Google Patents

Utilisations pharmaceutiques de (+)-bupropion optiquement pur Download PDF

Info

Publication number
CA2318960A1
CA2318960A1 CA002318960A CA2318960A CA2318960A1 CA 2318960 A1 CA2318960 A1 CA 2318960A1 CA 002318960 A CA002318960 A CA 002318960A CA 2318960 A CA2318960 A CA 2318960A CA 2318960 A1 CA2318960 A1 CA 2318960A1
Authority
CA
Canada
Prior art keywords
bupropion
administered
amount
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002318960A
Other languages
English (en)
Inventor
James W. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22110794&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2318960(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2318960A1 publication Critical patent/CA2318960A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des procédés et des compositions utilisant l'isomère (+) optiquement pur de bupropion, qui est un médicament puissant pour le traitement des dépressions, de la maladie de Parkinson, de l'obésité, de la prise de poids, des maladies à forme bipolaire, des troubles déficitaires de l'attention ou des troubles de conduite, des dysfonctionnements psychosexuels, de la boulimie, des troubles de l'alimentation ou d'une appétence de nourriture spécifique. Une telle composition peut être administrée par voie intraveineuse, par voie transdermique (timbre) ou par voie orale, éventuellement sous une forme à libération prolongée.
CA002318960A 1998-01-29 1999-01-28 Utilisations pharmaceutiques de (+)-bupropion optiquement pur Abandoned CA2318960A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7295598P 1998-01-29 1998-01-29
US60/072,955 1998-01-29
PCT/US1999/001952 WO1999038502A1 (fr) 1998-01-29 1999-01-28 Utilisations pharmaceutiques de (+)-bupropion optiquement pur

Publications (1)

Publication Number Publication Date
CA2318960A1 true CA2318960A1 (fr) 1999-08-05

Family

ID=22110794

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002318960A Abandoned CA2318960A1 (fr) 1998-01-29 1999-01-28 Utilisations pharmaceutiques de (+)-bupropion optiquement pur

Country Status (5)

Country Link
EP (1) EP1051166A1 (fr)
JP (1) JP2002501890A (fr)
AU (1) AU2483499A (fr)
CA (1) CA2318960A1 (fr)
WO (1) WO1999038502A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7537784B2 (en) 2003-08-08 2009-05-26 Biovail Laboratories International Srl Modified release tablet of bupropion hydrochloride

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6280763B1 (en) * 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
US6312716B1 (en) * 1999-05-10 2001-11-06 Peierce Management Llc Patch and method for transdermal delivery of bupropion base
US7671094B2 (en) 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
CN101534808A (zh) * 2005-06-27 2009-09-16 拜维尔实验室国际有限公司 丁氨苯丙酮盐的改良释放配制品
WO2015095713A1 (fr) * 2013-12-20 2015-06-25 Deuterx, Llc Méthodes pour traiter des troubles neurologiques ou d'autres troubles au moyen de bupropion enrichi en deutérium énantiopure
CA3092076A1 (fr) * 2018-02-23 2019-08-29 Axsome Therapeutics, Inc. Formes posologiques et procedes pour obtenir du bupropion enantiomeriquement enrichi ou pur
US20220249405A1 (en) * 2018-09-20 2022-08-11 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660274B2 (en) * 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11331285B2 (en) 2018-09-20 2022-05-17 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11433035B2 (en) 2018-09-20 2022-09-06 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11291639B2 (en) 2018-09-20 2022-04-05 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660273B2 (en) * 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US20200093760A1 (en) 2018-09-20 2020-03-26 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
KR20220066930A (ko) * 2019-09-20 2022-05-24 액섬 테라퓨틱스, 인크. 에난티오머적으로 풍부한 또는 순수한 부프로피온을 위한 제형 및 방법
US12180137B1 (en) 2024-05-01 2024-12-31 Deuterx, Llc Solid forms of enantiopure deuterium-enriched bupropion and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3885046A (en) * 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
GB9217295D0 (en) * 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
GB9315856D0 (en) * 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
WO1996039133A1 (fr) * 1995-06-06 1996-12-12 Neurobiological Technologies, Inc. Nouvelles 2-amino-3'-4'-methylene-dioxypropiophenones n-substituees

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7537784B2 (en) 2003-08-08 2009-05-26 Biovail Laboratories International Srl Modified release tablet of bupropion hydrochloride

Also Published As

Publication number Publication date
EP1051166A1 (fr) 2000-11-15
AU2483499A (en) 1999-08-16
WO1999038502A1 (fr) 1999-08-05
JP2002501890A (ja) 2002-01-22

Similar Documents

Publication Publication Date Title
US6110973A (en) Methods for treating obesity and weight gain using optically pure (-)-bupropion
TWI298255B (en) Use of optically pure (s.s)-reboxetine in the manufacture of a medicament for the treatment or prevention of fibromyalgia or another somatoform disorder
CA2318960A1 (fr) Utilisations pharmaceutiques de (+)-bupropion optiquement pur
US20030130355A1 (en) Therapeutic agents
EP0687472A2 (fr) Potentialisation d'un médicament par un antagoniste du récepteur sérotonine 1A
EP1051164A1 (fr) Usages pharmacologiques de (+)-bupropion pur
CA2138998A1 (fr) Compositions et methodes de traitement de la depression et d'autres troubles, qui contiennent de la sibutramine optiquement pure (-)
JP2003524613A (ja) （−）−ベンラファキシン誘導体並びにその製造方法および使用方法
JP2001503737A (ja) 糖尿病の発生を防止するためのシブトラミン類似体の利用
CA2139000A1 (fr) Compositions et methodes de traitement de la depression et d'autres troubles, qui contiennent de la sibutramine optiquement pure (+)
EP0759299A1 (fr) Potentialisation de la sérotonine
AU2349899A (en) Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-)-bupropion
EP0612242B1 (fr) Utilisation de l' isomere s(+) pur de fluoxetine pour la preparation d'un medicament contre la migraine
US20040115263A1 (en) Use of bupropion for treating restless legs syndrome
AU721924B2 (en) Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
SK3272001A3 (en) A new composition
WO1992013452A1 (fr) Procedes d'utilisation et compositions de r(-) fluoxetine
HK1013797A (en) Potentiation of drug response by a serotonin 1a receptor antagonist
AU6172699A (en) Methods and compositions utilizing pure S()isomer fluoxetine

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20050128